Skip to main content

Table 1 Clinical characteristics on admission

From: Clinical, radiological and functional outcomes in patients with SARS-CoV-2 pneumonia: a prospective observational study

Parameters Normal range Over all (39) CT improving at 3 month (31) CT not improving at 3 month (8)
Age (years, median and IQR) ≥ 18 62.5 (51.3–71) 59.2 (50.2–71) 69.4 (60.2–71.7)
Sex (female, n and %)   9 (23.1) 7 (22.6) 2 (25)
BMI > 25 kg/m2 (n and %)   27 (69.2) 21 (67.7) 6 (75)
Active smokers (n and %)   3 (7.7) 2 (6.4) 1 (12.5)
Previous smokers (n and %)   12 (30.8) 8 (25.8) 4 (50)
Smoking burden (p/y, mean ± SD)   10.4 ± 16.6 7.8 ± 14.9 20.7 ± 19.9
Allergies (n and %)   11 (28.2) 9 (29) 2 (33.3)
Flu vaccination on adm. (n and %)   12 (30.8) 9 (29) 4 (50)
Pneumococcal vaccination on adm. (n and %)   1 (2.6) 0 (0) 1 (12.5)
Length of stay (days, median and IQR)   15 (12–22) 15 (11–21) 15.5 (12–28.7)
Hypertension (n and %)   11 (28.2) 9 (29) 5 (62.5)
Diabetes (n and %)   5 (12.8) 4 (12.9) 1 (12.5)
Cardiovascular diseases (n and %)   7 (17.9) 5 (16.1) 2 (33.3)
Coronary heart disease (n and %)   4 (10.2) 2 (6.4) 2 (33.3)
Chronic respiratory diseases (n and %)   8 (20.5) 6 (19.4) 2 (33.3)
COPD (n and %)   3 (7.7) 2 (6.4) 1 (12.5)
Asthma (n and %)   5 (12.8) 4 (12.9) 1 (12.5)
Chronic kidney disease (n and %)   3 (7.7) 2 (6.4) 1 (12.5)
Malignancy (n and %)   4 (10.2) 3 (9.7) 1 (12.5)
Intensive care unit admission (n and %)   10 (25.6) 9 (29) 1 (12.5)
Invasive mechanical ventilation (n and %)   7 (17.9) 6 (19.4) 1 (12.5)
Rehab. after discharge (n and %)   7 (17.9) 6 (19.4) 1 (12.5)
Peak PCR (mg/l) (mean ± SD) 1–5 185.7 ± 147.4 178.5 ± 137.4 213.4 ± 189.6
Peak LDH (U/l) (mean ± SD) < 500 653.2 ± 348.5 693.4 ± 364.8 502.4 ± 240.3
Peak leukocytes (G/l) (mean ± SD) 4.2–10 8.9 ± 4.8 8.3 ± 3.8 11.1 ± 7.5
Peak lymphopenia (G/l) (mean ± SD) 1.5 – 2.5 0.7 ± 0.2 0.7 ± 0.2 0.6 ± 0.3
Peak thrombopenia (G/l) (mean ± SD) 150–400 185.5 ± 81.9 187.6 ± 72.6 177 ± 117
Peak d-dimer (mg/l) (mean ± SD) < 0.5 4.8 ± 10 5.3 ± 11.5 2.9 ± 2.9
Lympho. on adm. (G/l) (mean ± SD) 1.5–2.5 0.8 ± 0.3 0.9 ± 0.3 0.67 ± 0.3
Leuko. on adm. (G/l) (mean ± SD) 4.2–10 5.5 ± 2.3 5.5 ± 2.3 5.5 ± 2.4
Thrombo on adm. (G/l) (mean ± SD) 150–400 189.9 ± 74.7 190 ± 64.2 189.4 ± 112.4
PaO2 on adm. (kPa) (mean ± SD) > 8 9.3 ± 1.4 9.3 ± 1.5 9.2 ± 0.6
nt-proBNP on adm. (ng/l) (mean ± SD) < 450 275.7 ± 253.7 229.5 ± 219.3 488 ± 318.4
D-dimer (mg/l) (mean ± SD) < 0.5 1.1 ± 0.8 1.2 ± 0.9 0.9 ± 0.6
Antibiotics (n and %)   24 (61.5) 21 (67.7) 8 (37.5)
Hydroxychloroquine (n and %)   32 (82) 24 (77.4) 8 (100)
Remdesevir (n and %)   2 (5.1) 2 (6.4) 0 (0)
Tocilizumab (n and %)   4 (10.2) 4 (12.9) 0 (0)
Lopinavir-Ritonavir (n and %)   21 (53.8) 19 (61.3) 2 (25)
ACE-I, ARB treatment (n and %)   11 (28.2) 8 (25.8) 3 (37.5)
Anticoag. on adm. (n and %)   4 (10.2) 2 (6.4) 2 (25)
Antiplt. on adm. (n and %)   7 (17.9) 6 (19.4) 1 (12.5)
GGO on adm (n and %)   34 (89.5) 27 (87.1) 7 (87.5)
Consolidations on adm (n and %)   17 (43.6) 15 (48.4) 2 (25)
Fibrous bands on adm (n and %)   28 (71.8) 22 (71) 6 (75)